Neumora Therapeutics, Inc. Share Price

NASDAQ: NMRA

Small Cap

$1.50

-0.02

(-1.32%)

as on September 17, 2025 at 1:29 am IST

$₹

Neumora Therapeutics, Inc. Stock Performance

as on September 17, 2025 at 1:29 am IST

Day's High
$1.5
Day's Price Range
$1.57
$1.5
4.67%
Upside
52 Week's Low
52 Week's High
$0.61
52-Week Price Range
$17.19
$1.5
59.27%
Downside
1045.83%
Upside

Neumora Therapeutics, Inc. share price movements today

Previous Close: $1.52
Open: $1.52
Volume: 698.9K
Day's Low - High: $1.5 - $1.57
52 Week Low - High: $0.61 - $17.19

Neumora Therapeutics, Inc. Historical Returns

1 Month Return: -7.98 %
3 Month Return: + 89.16 %
1 Year Return: -87.21 %
3 Year Return: 0 %
5 Year Return: 0 %

Neumora Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Neumora Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$246.2M

EPS (TTM)

-1.4167

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-264.1M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

164230900.00%

Neumora Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neumora Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Neumora Therapeutics, Inc.	BUY	$246.2M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	252.04%	-505.15	-12.96%
Beone Medicines Ltd	NA	$39.0B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$100.3B	44.17%	27.85	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	1.78%	14.1	31.37%

Stock Returns calculator for Neumora Therapeutics, Inc. Stock including INR - Dollar returns

The Neumora Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Neumora Therapeutics, Inc. investment value today

Current value as on today

₹17,386

Returns

₹82,614

(-82.61%)

Returns from Neumora Therapeutics, Inc. Stock

₹87,212 (-87.21%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Neumora Therapeutics, Inc. Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Neumora Therapeutics, Inc.. Average target price of $7

Neumora Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Neumora Therapeutics, Inc..

What analysts predicted

78.57%UPSIDE

Target Price

Current Price

$1.5

Analyzed by

12 Analysts

Target

$7.00

Neumora Therapeutics, Inc. target price $7, a slight upside of 78.57% compared to current price of $1.5. According to 12 analysts rating.

Neumora Therapeutics, Inc. Stock's Interest Amongst Investors

Search interest for Neumora Therapeutics, Inc. Stock has decreased by -54% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 18, 2025 to September 17, 2025

Change:-54% versus previous 30 day period

Neumora Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	-1	0	0	0	-	-	-	-
Operating Income	-39	-42	-56	-114	-60	-63	-76	-62	-70	-54
EBITDA	-38	-41	-55	-100	-59	-63	-76	-62	-70	-54
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-35	-38	-53	-108	-53	-58	-72	-58	-67	-52
Income Tax Expense	-3	-3	-4	-5	-6	0	0	-	0	0
Net Income	-35	-38	-53	-108	-53	-58	-72	-58	-67	-52
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Neumora Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	-	-1	-2	0	-
Operating Income	-95	-237	-135	-188	-263
EBITDA	-95	-236	-135	-187	-242
Interest Expense	-	-	-	-	-
Depreciation	0	0	0	0	0
Income Before Tax	-99	-237	-130	-235	-243
Income Tax Expense	0	0	-4	0	0
Net Income	-99	-237	-130	-235	-243
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Neumora Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-38	-53	-108	-53	-58	-72	-58	-67	-52
Operating Cash Flow	-31	-47	-51	-42	-56	-33	-50	-59	-52
Investing Cash Flow	24	23	13	-150	21	156	-98	44	30
Financing Cash Flow	0	232	0	1	2	1	15	-	18
Change in Cash	-6	208	-38	-191	-32	126	-133	-15	-3

Neumora Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-99	-237	-130	-235	-243
Operating Cash Flow	-26	-75	-114	-163	-182
Investing Cash Flow	-11	0	-168	64	-70
Financing Cash Flow	230	293	115	231	21
Change in Cash	192	217	-167	133	-231

Insights on Neumora Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.1% return, outperforming this stock by 155.3%
NEGATIVE IMPACT
Price Dip
In the last 7 days, NMRA stock has moved down by -8.0%

About Neumora Therapeutics, Inc.

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Organisation	Neumora Therapeutics, Inc.
Headquarters	490 Arsenal Way, Watertown, MA, United States, 02472
CEO	Dr. Daljit Singh Aurora Pharm.D.
E-voting on shares	Click here to vote

Key Management of Neumora Therapeutics, Inc.

Name	Title
Dr. Joshua Pinto Ph.D.	President
Dr. Rajesh Manchanda Ph.D.	Chief Technical Operations Officer
Dr. Nicholas Brandon Ph.D.	Chief Scientific Officer
Mr. Jason G. Duncan J.D.	Chief Legal & Administrative Officer
Ms. Amy Sullivan	Chief Human Resources Officer
Ms. Lori Houle	Chief Quality Officer
Dr. Daljit Singh Aurora Pharm.D.	Chief Operationg & Development officer
Mr. Michael Lee Milligan	CFO & Principal Accounting Officer
Helen Rubinstein	Head of Investor Relations
Dr. Maryjo Chamberlain-Tharp Ph.D.	Chief Business Officer

FAQs

What is Neumora Therapeutics, Inc. share price today?

Neumora Therapeutics, Inc. share price today is $1.5 as on September 17, 2025 at 1:29 am IST at the close of the market. Neumora Therapeutics, Inc. share today touched a day high of $1.57 and a low of $1.5.

What is the 52 week high and 52 week low for Neumora Therapeutics, Inc. share?

Neumora Therapeutics, Inc. share touched a 52 week high of $17.19 on October 18, 2024 and a 52 week low of $0.61 on May 14, 2025. Neumora Therapeutics, Inc. stock price today i.e. September 17, 2025 at 1:29 am IST is closed at $1.5,which is 91.27% down from its 52 week high and 145.50% up from its 52 week low.

What is Neumora Therapeutics, Inc.'s market capitalisation today?

Neumora Therapeutics, Inc. market capitalisation is $0.00T as on September 17, 2025 at 1:29 am IST.

How to invest in Neumora Therapeutics, Inc. Stock (NMRA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Neumora Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neumora Therapeutics, Inc. Shares that will get you 1.0000 shares as per Neumora Therapeutics, Inc. share price of $1.5 per share as on September 17, 2025 at 1:29 am IST.

What is the minimum amount required to buy Neumora Therapeutics, Inc. Stock (NMRA) from India?

Indian investors can start investing in Neumora Therapeutics, Inc. (NMRA) shares with as little as ₹87.816 or $1 (as of September 17, 2025 at 6:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Neumora Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on September 17, 2025 at 6:37 pm IST). Based on Neumora Therapeutics, Inc. share’s latest price of $1.5 as on September 17, 2025 at 1:29 am IST, you will get 6.6667 shares of Neumora Therapeutics, Inc.. Learn more about fractional shares .